Selenium inhibition of survivin expression by preventing Sp1 binding to its promoter
Authors:
- 1 September 2007
- journal article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 6 (9) , 2572-2580
Abstract
Survivin, an antiapoptotic protein highly expressed in cancer, regulates multiple cellular network associated with cancer cell viability and drug resistance. Inhibition of survivin expression has been pursued as a valid cancer therapeutic target. In this study, we showed that selenium, an effective chemopreventive agent for many types of cancers, down-regulated survivin expression. Selenium inhibited survivin expression in both mRNA and protein levels in a dose- and time-dependent manner. Using a series of survivin promoter–luciferase constructs, a 37-bp DNA element in the survivin core promoter region that mediates the ability of selenium to inhibit survivin transcription was identified. Gel mobility shift assays and chromatin immunoprecipitation analyses revealed that selenium prevents the binding of Sp1 or Sp1-like proteins to the 37-bp cis-acting DNA element in the survivin promoter. Furthermore, inhibition of survivin expression by small interfering RNA enhanced selenium's inhibitory effects on cell growth, whereas overexpression of survivin in LNCaP human prostate cancer cells desensitized cancer cells to selenium effect, suggesting that the expression of survivin plays an important role in determining the response of cancer cells to selenium. Taken together, these results suggest that selenium down-regulated survivin expression by preventing the binding of Sp1 or Sp1-like proteins to the promoter of survivin, which contributes at least in part to the inhibitory effect of selenium on survivin gene transcription. In addition, down-regulation of survivin expression may account for one of the molecular mechanisms of the anticancer effects of selenium. [Mol Cancer Ther 2007;6(9):2572–80]Keywords
This publication has 54 references indexed in Scilit:
- Role of the SurvivinGene in PathophysiologyThe American Journal of Pathology, 2006
- Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA)The Prostate, 2006
- Mechanisms of selenium down-regulation of androgen receptor signaling in prostate cancerMolecular Cancer Therapeutics, 2006
- Selenium disrupts estrogen receptor α signaling and potentiates tamoxifen antagonism in endometrial cancer cells and tamoxifen-resistant breast cancer cellsMolecular Cancer Therapeutics, 2005
- Attenuation of Estrogen Receptor α (ERα) Signaling by Selenium in Breast Cancer Cells via Downregulation of ERα Gene ExpressionBreast Cancer Research and Treatment, 2005
- Diverse Effects of Methylseleninic Acid on the Transcriptional Program of Human Prostate Cancer CellsMolecular Biology of the Cell, 2004
- Inorganic Selenium Retards Progression of Experimental Hormone Refractory Prostate CancerJournal of Urology, 2004
- Survivin, versatile modulation of cell division and apoptosis in cancerOncogene, 2003
- IAP proteins: blocking the road to death's doorNature Reviews Molecular Cell Biology, 2002
- Ribozyme-mediated attenuation of survivin expression sensitizes human melanoma cells to cisplatin-induced apoptosisJournal of Clinical Investigation, 2002